Cutaneous B-Cell Lymphoma: Relapsed/Refractory

Cutaneous B-Cell Lymphoma

Relapsed/Refractory

The term “relapsed” refers to disease that reappears or grows again after a period of remission.

The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.

Secondary therapy for relapsed (disease returns after treatment) CBCL can include surgery, topical treatments, injected steroids, or radiation. Slow-growing CBCLs rarely transform into more aggressive types of lymphoma. For diseases that become widespread (systemic), regimens that may be used include:

  • Rituximab (Rituxan), either alone or in combination with chemotherapy.

Treatments Under Investigation

Many treatments at various stages of drug development are currently being tested in clinical trials for relapsed or refractory CBCL, including:

  • Lenalidomide (Revlimid)
  • Bendamustine (Treanda)
  • Rituximab (Rituxan)

Learn More

To learn more about CBCL, download the Cutaneous Lymphoma Fact Sheet. Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Helpline at (800) 500-9976 or helpline@lymphoma.org.

Additional Resources

To learn more about CBCL, download the Cutaneous B-Cell Lymphoma Fact Sheet.

Events

Lymphoma Talk: Los Angeles

Westdrift Manhattan Beach 1400 Parkview Avenue, Manhattan Beach, California

Lymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides […]